Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity

合作伙伴关系将扩大Evotec在代谢疾病，特别是肥胖领域的分子患者数据库

Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics

Evotec将利用其领先的PanOmics技术生成大型组学数据集，包括转录组学、蛋白质组学和代谢组学

Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration

里尔大学医院将从其ABOS生物库中提供人类生物样本和相关临床数据，并将收集特定的人类生物样本进行合作

All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets

各方将根据人类数据集共同确定和验证肥胖和其他代谢疾病的新关键机制

HAMBURG, GERMANY / ACCESSWIRE / May 30, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private subsidiary of Inserm) to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases..

德国汉堡/ACCESSWIRE/2024年5月30日/Evotec SE（法兰克福证券交易所：EVT，MDAX/TecDAX，ISIN：DE0005664809；纳斯达克：EVO）今天宣布，该公司与Inserm，法国国立卫生与医学研究所，里尔大学医院和Inserm Transfer（Inserm的私人子公司）建立了合作关系，以确定肥胖和代谢疾病的新治疗靶点以及诊断和预后标志物。。

Lille University Hospital is the sponsor of the clinical study entitled ABOS / DIABOMICS (Biological Atlas of Severe Obesity). In the framework of this study, started in 2012, Lille University Hospital develops and maintains the ABOS Biobank composed of a biobank and different associated databases dedicated to the study of obesity and its comorbidities..

里尔大学医院是名为ABOS/糖尿病（严重肥胖生物图谱）的临床研究的赞助商。在2012年开始的这项研究的框架内，里尔大学医院开发并维护了ABOS生物库，该生物库由一个生物库和致力于肥胖及其合并症研究的不同相关数据库组成。。

Obesity, a medical condition characterised by an excess accumulation of fat cells and uncontrolled ectopic fat deposition in the body, is currently recognised as one of the most important public health problems. It is estimated that over one billion adults globally will be affected by 2030. The strategic partnership between Evotec, Inserm, Lille University Hospital and Inserm Transfert aims at identifying novel multi-modality therapeutic targets.

肥胖是一种以脂肪细胞过度积累和体内不受控制的异位脂肪沉积为特征的医学疾病，目前被认为是最重要的公共卫生问题之一。据估计，到2030年，全球将有超过10亿成年人受到影响。Evotec，Inserm，里尔大学医院和Inserm Transfert之间的战略合作伙伴关系旨在确定新的多模式治疗目标。

Evotec will gain access to a large patient cohort with severe obesity for the longitudinal assessment of metabolic outcomes after bariatric surgery-induced weight loss. The cohort consists of more than 8,000 human samples. Evotec will support the recruitment of 200 additional subjects within the next two years..

Evotec将获得一个严重肥胖的大型患者队列，用于减肥手术引起的体重减轻后代谢结果的纵向评估。该队列由8000多个人类样本组成。Evotec将在未来两年内支持招募200名额外科目。。

Under the agreement, Lille University Hospital will provide human biological samples and associated clinical data from its ABOS biobank and will collect specific human biological samples for the collaboration. Evotec will perform various omics studies on cohort samples to generate large omics data sets including transcriptomics, proteomics, and metabolomics data to better understand the etiology of metabolic diseases like metabolic dysfunction-associated steatohepatitis ('MASH'), obesity, diabetes, and cardiovascular disease.

根据协议，里尔大学医院将从其ABOS生物库中提供人类生物样本和相关临床数据，并将收集特定的人类生物样本用于合作。Evotec将对队列样本进行各种组学研究，以生成大型组学数据集，包括转录组学，蛋白质组学和代谢组学数据，以更好地了解代谢性疾病的病因，如代谢功能障碍相关的脂肪性肝炎（“MASH”），肥胖，糖尿病和心血管疾病。

These PanOmics data will feed into Evotec's proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data. The data will be analysed by all parties to identify and validate key mechanisms of obesity and other metabolic diseases..

这些PanOmics数据将输入Evotec专有的翻译分子患者数据平台E.MPD，该平台是分子患者数据的中央数据库。各方将对数据进行分析，以确定和验证肥胖和其他代谢疾病的关键机制。。

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'We are excited to enter this partnership with Inserm and Lille University Hospital accessing a cohort of obese patients that is extremely well characterised. Currently over 40% of the US population suffers from obesity. The condition is a major health threat as it is connected to a plethora of other medical conditions such as type 2 diabetes, hypertension, cardiovascular disease, congestive heart failure, kidney disease and non-alcoholic fatty liver disease.

Evotec首席科学官Cord Dohrmann博士评论道：“我们很高兴与Inserm和里尔大学医院建立这种合作关系，接触到一组特征非常明确的肥胖患者。目前，超过40%的美国人口患有肥胖症。这种疾病是一种主要的健康威胁，因为它与多种其他疾病有关，如2型糖尿病、高血压、心血管疾病、充血性心力衰竭、肾脏疾病和非酒精性脂肪肝。

This collaboration will help to understand obesity as a disease, something not achieved despite recent breakthroughs. Expanding our understanding of the key molecular mechanisms driving disease progression will allow us to identify and develop more effective but also safer treatment options than currently available.'.

这种合作将有助于将肥胖理解为一种疾病，尽管最近取得了突破，但这一点尚未实现。扩大我们对驱动疾病进展的关键分子机制的理解，将使我们能够确定和开发比目前更有效但更安全的治疗选择。”。

Prof. Francois Pattou, Translational Research Laboratory for Diabetes, Inserm UMR 1190 (under the joint supervision of Inserm, University of Lille and Lille University Hospital), PhD at Lille University Hospital, and Chairman of the Scientific Committee of Lille University Hospital ABOS Biobank, added: 'Collaborating on cutting-edge science with a human data-centric approach gives us a unique opportunity to discover novel treatments for the benefit of patients living with obesity and metabolic diseases.

Inserm UMR 1190糖尿病转化研究实验室（在Inserm、里尔大学和里尔大学医院的联合监督下），里尔大学医院博士，里尔大学医院ABOS生物库科学委员会主席Francois Pattou教授补充道：“通过以人类数据为中心的方法在前沿科学上的合作，为我们提供了一个独特的机会，可以发现新的治疗方法，为肥胖和代谢疾病患者带来益处。

The strong know-how and capabilities from Evotec will enable us to further strengthen and advance our research efforts within obesity and metabolic diseases based on human-relevant biology, to contribute to our overall mission of improving human health for all.'.

Evotec强大的专业知识和能力将使我们能够进一步加强和推进基于人类相关生物学的肥胖和代谢疾病的研究工作，为我们改善人类健康的总体使命做出贡献。”。

Prof. Bart Staels, Nuclear receptors, cardiovascular diseases and diabetes Laboratory, Inserm UMR 1011 (under the joint supervision of Inserm, Lille University Hospital, University of Lille and Institut Pasteur of Lille), said: 'We are very excited about the collaboration and are confident that the combination of Evotec's excellent expertise and our commitment to therapeutic innovation, translational research, and multidisciplinary approaches, will open up new possibilities in discovery and development of novel drugs targeting obesity and metabolic diseases, with the potential to make a difference for patients living with these conditions.'.

Inserm UMR 1011核受体，心血管疾病和糖尿病实验室Bart Staels教授（在Inserm，里尔大学医院，里尔大学和里尔巴斯德研究所的联合监督下）说：“我们对合作感到非常兴奋，并相信Evotec的优秀专业知识与我们对治疗创新，转化研究和多学科方法的承诺相结合，将为发现和开发针对肥胖和代谢疾病的新药开辟新的可能性，并有可能为患有这些疾病的患者带来改变。”。

Noémie Pellegrin, Director of Industry Partnerships and Entrepreneurship of Inserm Transfert, adds: We are delighted with this research partnership, which capitalises on the wealth of know-how within the Inserm laboratories, the quality data from Lille University Hospital and the cutting-edge molecular translational technologies developed by Evotec.

Inserm Transfert的行业合作与创业主管诺米·佩莱格林（Noémie Pellegrin）补充道：我们对这种研究合作关系感到高兴，它利用了Inserm实验室内丰富的专有技术、里尔大学医院的质量数据以及Evotec开发的尖端分子转化技术。

This collaboration will advance our understanding of obesity and associated metabolic diseases through the identification of key molecular mechanisms and new therapeutic targets..

这种合作将通过确定关键的分子机制和新的治疗靶点，增进我们对肥胖和相关代谢疾病的理解。。

About Obesity

关于肥胖

Obesity is defined as abnormal or excessive fat accumulation that presents a risk to health. A body mass index ('BMI') over 30 is obese. However, BMI categories for defining obesity vary by age and gender in infants, children, and adolescents. The issue has grown to epidemic proportions and obesity constitutes a major public health challenge that undermines social and economic development.

肥胖被定义为异常或过度脂肪堆积，对健康构成风险。体重指数（BMI）超过30是肥胖的。然而，定义肥胖的BMI类别因婴儿，儿童和青少年的年龄和性别而异。这个问题已经发展到流行病的程度，肥胖症构成了破坏社会和经济发展的重大公共卫生挑战。

The worldwide prevalence of obesity nearly tripled between 1975 and 2016. The World Obesity Federation estimates that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Once associated with high-income countries, obesity is now also prevalent in low-and middle-income countries, including among lower socio-economic groups.

1975年至2016年间，全球肥胖患病率几乎翻了两番。世界肥胖联合会估计，到2020年，全球约有7.7亿成年人受到肥胖的影响，到2030年，这一数字预计将超过10亿。肥胖曾经与高收入国家有关，现在在低收入和中等收入国家也很普遍，包括在较低的社会经济群体中。

Overweight and obesity are caused by many factors including behaviours like eating patterns, lack of sleep or physical activity, and some medicines, as well as genetics and family history. Obesity is a chronic health condition that raises the risk for heart disease and is linked to many other health problems, including MASH, type 2 diabetes and cancer..

超重和肥胖是由许多因素引起的，包括饮食习惯、睡眠不足或体力活动不足、一些药物以及遗传和家族史等行为。肥胖是一种慢性健康状况，会增加患心脏病的风险，并与许多其他健康问题有关，包括MASH、2型糖尿病和癌症。。

About E.MPD

关于E.MPD

E.MPD, Evotec's translational molecular patient database, is one of the largest and highest quality molecular databases globally. Evotec's integrated technology platforms show that the best way to effectively treat disease is to identify underlying disease mechanisms and find the most suitable therapy on the basis of molecular data guiding all experimental processes towards early disease relevance.

E、 MPD是Evotec的翻译分子患者数据库，是全球最大且质量最高的分子数据库之一。Evotec的综合技术平台表明，有效治疗疾病的最佳方法是确定潜在的疾病机制，并根据分子数据找到最合适的治疗方法，指导所有实验过程与早期疾病相关。

Therefore, data aggregation, integration, and the precise analysis of data is the critical path to effective and affordable medicine in the future..

因此，数据聚合，集成和数据的精确分析是未来有效且负担得起的药物的关键途径。。

E.MPD serves as the backbone for data-driven partnerships that will lead to innovative new medicines, better patient stratification, and potentially pave the way towards a new paradigm of more effective diagnostic and preventative healthcare. Through gathering and analysing patient-derived data in combination with AI/ML tools, Evotec is also able to better predict both safety and efficacy indicators in drug development..

E、 MPD是数据驱动的合作伙伴关系的支柱，这将导致创新的新药，更好的患者分层，并可能为更有效的诊断和预防保健的新范式铺平道路。通过结合AI/ML工具收集和分析患者来源的数据，Evotec还能够更好地预测药物开发中的安全性和有效性指标。。

About Inserm

关于Inserm

Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient's bedside.

Inserm成立于1964年，是一家公共科学技术研究所，由法国卫生部和研究部共同管理。该研究所致力于生物医学研究和人类健康，并参与从实验室到患者床边的所有活动。

It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields. www.inserm.fr.

它还与世界上最负盛名的研究机构合作，致力于这些领域的科学挑战和进步。www.inserm.fr。

About Lille University Hospital

关于里尔大学医院

With over 16,000 professionals and 10 hospitals on a single campus, the Centre Hospitalier Universitaire de Lille is one of the four largest university hospital centers in France, and one of the largest in Northern Europe. As a regional referral centre as well as teaching, innovation and research hospital, it serves the 6 million inhabitants of the Hauts-de-France region.

里尔大学中心医院拥有16000多名专业人员和10家医院，是法国四大大学医院中心之一，也是北欧最大的医院中心之一。作为一个地区转诊中心以及教学、创新和研究医院，它为法兰西州600万居民提供服务。

Lille University Hospital is strongly committed to the development of therapeutic innovation and clinical research. Its research strategy focuses on the early diagnosis and treatment of multi-factorial diseases, including cancer, neuroscience, cardiovascular, metabolic, inflammatory and infectious pathologies.

里尔大学医院致力于治疗创新和临床研究的发展。其研究策略侧重于多因素疾病的早期诊断和治疗，包括癌症，神经科学，心血管，代谢，炎症和传染病。

For further information: www.chu-lille.fr, X/Twitter and LinkedIn..

欲了解更多信息，请访问www.chu-lille.fr、X/Twitter和LinkedIn。。

About Inserm Transfert

关于Inserm转移

Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for value creation of Inserm and its academic partners' innovations in human health and promotes long-term technology transfers in line with international best practices.

Inserm Transfert是法国国家卫生与医学研究所（Inserm）的私人子公司，负责为Inserm及其学术合作伙伴在人类健康方面的创新创造价值，并根据国际最佳实践促进长期技术转让。

Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (Concession de Service Public) the entire innovation value chain and the transfer of knowledge from Inserm's research laboratories to industry, from invention disclosure to industrial partnerships and startups incorporation.

Inserm Transfert SA成立于2000年，根据公共服务管理合同（公共服务特许权）管理整个创新价值链，并将知识从Inserm的研究实验室转移到行业，从发明披露到产业合作伙伴关系和初创公司。

Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases and cohorts. For more information: www.inserm-transfert.com.

Inserm Transfert还提供与建立和管理国家、欧洲和国际项目有关的服务，以及支持临床研究和健康数据/数据库和队列的技术转让。有关更多信息，请访问www.inserm-transfert.com。

About Evotec SE

关于Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec是一家生命科学公司，拥有独特的商业模式，致力于发现和开发高效的治疗方法，并将其提供给患者。该公司的多模式平台包括创新技术、数据和科学的独特组合，用于发现、开发和生产一流和一流的药品。

Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.

Evotec为所有前20大制药公司和800多家生物技术公司、学术机构以及其他医疗保健利益相关者提供高价值的合作伙伴关系和解决方案。Evotec在目前服务不足的广泛治疗领域开展了战略活动，包括。

neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.

神经病学、肿瘤学以及代谢和传染病。在这些专业领域内，Evotec旨在创建世界领先的创新疗法共同拥有的管道，迄今为止，已建立了200多个专有和共同拥有的研发项目组合，从早期发现到临床开发。

Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn..

Evotec在全球运营，拥有5000多名高素质员工。该公司在欧洲和美国的网站提供高度协同的技术和服务，并作为互补的卓越集群运营。有关更多信息，请访问www.evotec.com，并在X/Twitter@evotec和LinkedIn上关注我们。。

Forward-looking-statements

前瞻性声明

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements.

本公告包含有关未来事件的前瞻性声明，包括Evotec证券的拟议发售和上市。诸如“预期”、“相信”、“可能”、“估计”、“期望”、“打算”、“可能”、“可能”、“计划”、“潜力”、“应该”、“目标”、“将会”等词语以及这些词语和类似表达的变体旨在识别前瞻性陈述。

Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made.

这些声明包括对Evotec收入预期、集团息税折旧摊销前利润和未经授权的研发费用的评论。这些前瞻性陈述基于Evotec在做出这些陈述时认为合理的可用信息以及期望和假设。

No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec.

无法保证这些期望将被证明是正确的。这些报表涉及已知和未知的风险，并基于一些假设和估计，这些假设和估计固有地受到重大不确定性和意外事件的影响，其中许多不受Evotec的控制。

Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based..

Evotec明确否认有义务或承诺公开发布本文所含任何前瞻性声明的任何更新或修订，以反映Evotec对此预期的任何变化，或任何声明所依据的事件、条件或情况的任何变化。。

For further information, please contact:

欲了解更多信息，请联系：

Media

媒体

Gabriele Hansen

加布里埃尔·汉森

SVP Head of Global Corporate Communications

全球企业传播高级副总裁

Gabriele.Hansen@evotec.com

Gabriele.Hansen@evotec.com

Hinnerk Rohwedder

Hinnerk Rohwedder

Director of Global Corporate Communications

全球企业传播总监

Hinnerk.Rohwedder@evotec.com

Hinnerk.Rohwedder@evotec.com

Investor Relations

投资者关系

Volker Braun

弗尔克·布劳恩

EVP Head of Global Investor Relations & ESG

全球投资者关系和ESG执行副总裁

Volker.Braun@evotec.com

Volker.Braun@evotec.com

SOURCE: Evotec SE

来源：Evotec SE

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿